GLP-1 and Peptide Quiz: Which Is Right for Me?

It depends on your goal, health history and how you pay. For weight loss, the FDA-approved options are Wegovy (pill or shot), Zepbound and Foundayo. For type 2 diabetes, they are Ozempic (pill or shot) and Mounjaro. In a 72-week head-to-head trial (SURMOUNT-5) of 751 adults with obesity, people on tirzepatide (Zepbound) lost about 20% of their weight vs about 14% on semaglutide (Wegovy). The maker of tirzepatide paid for it. Your doctor decides which one fits you.

The FDA label approves Wegovy for long-term weight loss in adults with obesity, or with overweight plus at least one weight-related health problem, and the shot for ages 12 and up with obesity. In its main trials, adults had a BMI of 30 or more, or 27 to 29.9 with a weight-related condition. It is also approved to lower heart risk in adults with heart disease and obesity or overweight, and (the shot) for MASH fatty liver with F2 to F3 scarring. Do not use it if you or your family had medullary thyroid cancer, or if you have MEN 2.

The FDA-approved weekly weight loss shots are the Wegovy shot (semaglutide) and Zepbound (tirzepatide). Zepbound led to more weight loss in the SURMOUNT-5 head-to-head trial. Maker self-pay prices on Oct 30, 2026: Zepbound $299 to $449 per 28-day fill, Wegovy shot $199 to $399. Side effects, health history and coverage matter as much as the average result.

Both are FDA-approved weekly shots for long-term weight loss. In the 72-week SURMOUNT-5 trial, people on Zepbound (tirzepatide) lost about 20% of their weight vs about 14% on Wegovy (semaglutide); the maker of tirzepatide paid for it. Wegovy also comes as a daily pill and is approved to lower heart attack, stroke and heart death risk in adults with heart disease and obesity or overweight. Zepbound is also approved for moderate to severe sleep apnea in adults with obesity. Maker self-pay prices on Oct 30, 2026: Zepbound $299 to $449, Wegovy shot $199 to $399 per fill. The quiz weighs your goal, cost and health flags; your doctor decides.

The FDA label approves Zepbound for long-term weight loss in adults with obesity, or with overweight plus at least one weight-related health problem, together with diet and exercise. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity. Do not use it if you or your family had medullary thyroid cancer, or if you have MEN 2. Your doctor decides if you qualify.

Partly. It checks your answers against what each FDA label approves and who should not use it (for example, medullary thyroid cancer or MEN 2), and shows the cost for how you pay, including the $50 Medicare GLP-1 Bridge copay if you may qualify. It cannot confirm that you are eligible: only a licensed prescriber can, and your insurer or Medicare plan decides coverage.

Yes. If your goal is joint pain, injury recovery, muscle or healthy aging, the quiz shows the peptides people ask about, with their FDA status and separate evidence and safety ratings. No peptide is FDA approved for those goals (tesamorelin is approved only for HIV-related belly fat), and no GLP-1 is approved for them either, so the quiz says that first.

GLP-1 shots such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are peptides themselves, but they are FDA approved, made under FDA rules and tested in large trials. The Foundayo pill (orforglipron) works on the same GLP-1 receptor but is not a peptide. Most other peptides sold online, such as BPC-157, are not FDA approved for any use.

No. It is an educational tool. It does not diagnose anything, does not give doses, and cannot promise a result. It shows what the FDA labels say and what each option costs, so you can have a better talk with your doctor.

Not if it was medullary thyroid cancer (MTC), or if you have MEN 2. The FDA labels for all 7 options here say do not use them (a contraindication) if you or your family had medullary thyroid cancer (MTC), or if you have MEN 2. Each label has a boxed warning: these medicines caused thyroid C-cell tumors in rodents, and it is unknown if they do in people. Ask your doctor about other kinds of thyroid problems.

No. BPC-157 is not FDA approved for anything, it is not a weight loss medicine, and it has only 3 tiny reports in people (30 people in all), with no fake-shot group to compare. Since October 28, 2026, HHS says it will not take action against licensed pharmacies and doctors that make BPC-157 for a patient with a prescription, under strict rules. That is not FDA approval.

No. The quiz runs in your browser. Nothing is sent to us or stored. If you copy the share link, your choices are saved in the link itself (after the # sign), and only people you send it to can see them.